Study design. Note: ¹administrative censoring rules in both Komodo and Acentrus cohorts included censoring patients at the earliest of a within-class BTKi switch, anti-CD20/venetoclax add-on within 6 months, DA outside of 3-12 months, participation in a clinical trial, treatment discontinuation, end of continuous enrollment (only available in Komodo), death (only available in Acentrus), or end of data availability.